| Drug Type Small molecule drug | 
| Synonyms G-1, LNS 8801 | 
| Target | 
| Action agonists | 
| Mechanism GPER1 agonists(G protein-coupled estrogen receptor 1 agonists) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePhase 2/3 | 
| First Approval Date- | 
| RegulationOrphan Drug (United States) | 
| Molecular FormulaC21H18BrNO3 | 
| InChIKeyVHSVKVWHYFBIFJ-HKZYLEAXSA-N | 
| CAS Registry- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Melanoma, Cutaneous Malignant | Phase 3 | United States  | 06 Aug 2025 | |
| Unresectable Melanoma | Phase 3 | United States  | 06 Aug 2025 | |
| Advanced cancer | Phase 2 | United States  | 21 Oct 2019 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | United States  | 21 Oct 2019 | |
| Colorectal Cancer | Phase 2 | United States  | 21 Oct 2019 | |
| Lymphoma | Phase 2 | United States  | 21 Oct 2019 | |
| metastatic non-small cell lung cancer | Phase 2 | United States  | 21 Oct 2019 | |
| Uveal Melanoma | Phase 2 | United States  | 21 Oct 2019 | |
| Pancreatic Ductal Adenocarcinoma | Preclinical | United States  | 01 Jan 2020 | |
| Pancreatic Ductal Adenocarcinoma | Preclinical | United States  | 01 Jan 2020 | 
| Phase 1 | Melanoma germline GPER | 9 | geevwnrepx(hwubvxahhz) = G3 and G1 cfzrxkhbsp (sbfzdkmemv ) View more | Positive | 14 Sep 2024 | ||
| Phase 1/2 | Refractory Melanoma consensus germline GPER | 10 | sfkybfwwti(ytdedegtjf) = gwkwvnwnkm wqlimbguwp (wacxjtvuhu ) View more | Positive | 02 Nov 2023 | ||
| Phase 1/2 | - | cztpceigqv(sprlbwoyrw) = oczlnfopqx vpaluqxzqw (cdynitudyr ) View more | - | 22 Oct 2023 | |||
| NCT04130516 (ASCO2023) Manual | Phase 1/2 | 15 | nmhjaklzng(cwboyrnvmv) = 4 of 8 monotherapy patients had AEs potentially related to study drug (all grade 1), with no AEs occurring in more than one patient. 6 of 7 combination patients had AEs potentially related to study drugs (grades 1-2), with fatigue occurring in more than one patient. uegwgyndez (mufeenfzrb ) | Positive | 31 May 2023 | ||
| Phase 1/2 | 13 | wiuetgwzhx(mgjbnjcwcb) = LNS8801 was identified as 125 mg daily as a monotherapy and in combination with  pembrolizumab (200 mg every 3 weeks) vqntbjfcvt (ldkpeynwlm ) | Positive | 06 Jun 2022 | |||
| NCT04130516 (ASCO2022) Manual | Phase 1 | 13 | odgbqyrlyl(uilkdyboeh) = bnosphlvqm sxtxezpgsc (ezacqfpnkp ) View more | Positive | 02 Jun 2022 | ||
| Phase 1 | 33 | dptdrgavrt(uvvmtlawve) = rqqghqfgad ehqdjjrowe (mwkgnyrrfx ) View more | Positive | 20 May 2021 | |||
| dptdrgavrt(uvvmtlawve) = knqszsfats ehqdjjrowe (mwkgnyrrfx ) View more | 





